Can-Fite BioPharma (NYSE:CANF) Receives Buy Rating from D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Can-Fite BioPharma (NYSE:CANF) in a report published on Tuesday,Benzinga reports. They currently have a $11.00 price objective on the stock.

Can-Fite BioPharma Trading Up 0.6%

Shares of NYSE:CANF opened at $0.65 on Tuesday. The stock has a 50 day moving average of $0.76 and a 200 day moving average of $1.08. The company has a market cap of $2.30 million, a PE ratio of -0.36 and a beta of 1.06. Can-Fite BioPharma has a 12-month low of $0.63 and a 12-month high of $3.12.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Rhumbline Advisers increased its position in Can-Fite BioPharma Ltd. (NYSE:CANF) by 42.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 38,268 shares of the company’s stock after buying an additional 11,388 shares during the period. Rhumbline Advisers owned about 1.08% of Can-Fite BioPharma worth $57,000 at the end of the most recent quarter. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.